Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12748
Title: Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial.
Authors: Nichol, Alistair;French, Craig J;Little, Lorraine;Presneill, Jeffrey;Cooper, David James;Haddad, Samir;Duranteau, Jacques;Huet, Olivier;Skrifvars, Markus;Arabi, Yaseen;Bellomo, Rinaldo
Institutional Author: EPO-TBI Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
Affiliation: Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. alistair.nichol@monash.edu.
Department of Intensive Care, Western Health, Gordon Street, Footscray, 3011, Australia. craig.french@wh.org.au.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. lorraine.little@monash.edu.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. intensive@fastmail.com.au.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. jamie.cooper@monash.edu.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. haddads55@yahoo.com.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. jacques.duranteau@bct.aphp.fr.
Department of Anesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire La Cavale Blanche Université de Bretagne Ouest, 29609, Brest Cedex, France. olivier.huet@chu-brest.fr.
Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, PO Box 266, FIN-00029, Helsinki, Finland. Markus.Skrifvars@hus.fi.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. Arabi@NGHA.MED.SA.
Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne, 3004, Australia. rinaldo.bellomo@austin.org.au.
Issue Date: 8-Feb-2015
Citation: Trials 2015; 16(): 39
Abstract: Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory and clinical studies demonstrate a possible beneficial effect of erythropoietin in improving outcomes in the traumatic brain injury cohort. However, there are concerns regarding the association of erythropoietin and thrombosis in the critically ill. A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised trial is currently underway to address this hypothesis.The erythropoietin in traumatic brain injury trial is a stratified prospective, multi-centre, randomised, blinded, parallel-group, placebo-controlled phase III trial. It aims to determine whether the administration of erythropoietin compared to placebo improves neurological outcome in patients with moderate or severe traumatic brain injury at six months after injury. The trial is designed to recruit 606 patients between 15 and 65 years of age with severe (Glasgow Coma Score: 3 to 8) or moderate (Glasgow Coma Score: 9 to 12) traumatic brain injury in Australia, New Zealand, Kingdom of Saudi Arabia, France, Finland, Germany and Ireland. Trial patients will receive either subcutaneous erythropoietin or placebo within 24 hours of injury, and weekly thereafter for up to three doses during the intensive care unit admission. The primary outcome will be the combined proportion of unfavourable neurological outcomes at six months: severe disability or death. Secondary outcomes will include the rate of proximal deep venous thrombosis detected by compression Doppler ultrasound, six-month mortality, the proportion of patients with composite vascular events (deep venous thrombosis, pulmonary embolism, myocardial infarction, cardiac arrest and cerebrovascular events) at six months and quality of life with health economic evaluations.When completed, the trial aims to provide evidence on the efficacy and safety of erythropoietin in traumatic brain injury patients, and to provide clear guidance for clinicians in their management of this devastating condition.Australian New Zealand Clinical Trials registry: ACTRN12609000827235 (registered on 22 September 2009). Clinicaltrials.gov: NCT00987454 (registered on 29 September 2009). European Drug Regulatory Authorities Clinical Trials: 2011-005235-22 (registered on 18 January 2012).
Internal ID Number: 25884605
URI: http://ahro.austin.org.au/austinjspui/handle/1/12748
DOI: 10.1186/s13063-014-0528-6
URL: http://www.ncbi.nlm.nih.gov/pubmed/25884605
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
25884605.pdf579.61 kBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.